Augmented Berlin–Frankfurt–Münster (ABFM) pediatric-based chemotherapy regimen

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%

The pediatric-based ABFM regimen produced equivalent overall survival and complete remission duration compared to the adult hyper-CVAD regimen in adolescents and young adults with Ph-negative ALL, wit

Effect: null; 5-year OS 60% vs 60%